Sebastiano Buti

A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable

Alessio Cortellini, Melissa Bersanelli, Sebastiano Buti et al. · Journal for ImmunoTherapy of Cancer · 2019 · 400 citations · Full text

Association of Systemic Inflammation Index and Body Mass Index with Survival in Patients with Renal Cell Cancer Treated with Nivolumab

Ugo De Giorgi, Giuseppe Procopio, Diana Giannarelli et al. · Clinical Cancer Research · 2019 · 233 citations · Full text

Clinical Outcomes of Patients with Advanced Cancer and Pre-Existing Autoimmune Diseases Treated with Anti-Programmed Death-1 Immunotherapy: A Real-World Transverse Study

Alessio Cortellini, Sebastiano Buti, Daniele Santini et al. · The Oncologist · 2019 · 214 citations · Full text

Immunology, Immunoediting, Pathology +21

Correlations Between the Immune-related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC Patients

Alessio Cortellini, Rita Chiari, Biagio Ricciuti et al. · Clinical Lung Cancer · 2019 · 174 citations

Cancer Immunosurveillance, Anti-pd1 Immunotherapy, Immunodeficiencies +9

Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): a double-blind, randomised, phase 3 trial

Robert J. Motzer, Paul Russo, Viktor Grünwald et al. · The Lancet · 2023 · 159 citations · Full text

Urology, Surgical Oncology, Genitourinary Cancer +7